Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.
Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.